
|Articles|November 15, 2007
First-line treatment for neovascular AMD
Combination therapy using photodynamic therapy and verteporfin (Visudyne, Novartis) as well as bevacizumab (Avastin, Genentech) can be effective in patients with age-related macular degeneration (AMD), particularly when patients are naïve to treatment, according to results from a patient registry.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Pickleball, fireworks, eyecare in space, and IRIS registry data among lead stories from day 1 of AAO 2025
2
Preclinical study suggests synaptic regeneration may offer new pathway to treat glaucoma
3
AAO 2025: The outcomes of the VERONA and DAVIO-2 studies set up continued phase 3 research
4
Tensions rise between STAAR and Broadwood as proposed Alcon deal nears vote
5